Clinical trial
Phenotypic Features and Prognostic Value of Anti-Ro52 (TRIM-21) Antibodies in Connective Tissue Diseases
NCT03565601 is registered in ClinicalTrials.gov with Central Hospital, Nancy, France as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Phenotypic Features and Prognostic Value of Anti-Ro52 (TRIM-21) Antibodies in Connective Tissue Diseases
- Lead sponsor
- Central Hospital, Nancy, France
- Phase
- Observational
- Overall status
- Unknown status
- Start date
- January 1, 2019
- Completion date
- September 1, 2020
- Enrollment
- 400 (estimated)
- Sites
- 4
Conditions
As the registry lists them; a condition with its own page is linked.